4D Molecular Therapeutics FDMT
NASDAQ FDMT
$12.99 +0.53 (+4.25%)
At close: Nov 11, 2026 · 4:00 PM EST

4D Molecular Therapeutics (FDMT) Return on Capital Employed [ROCE] (2021 - 2026)

Updated

4D Molecular Therapeutics (FDMT) posted Return on Capital Employed [ROCE] of -43.31% for Q2 2026, up 4.58 percentage points from -47.90% a year earlier but down 7.14 percentage points from the prior quarter.

Analysis

4D Molecular Therapeutics (FDMT) Return on Capital Employed [ROCE] (2021 - 2026) Analysis & Trends

For FY2025, 4D Molecular Therapeutics' Return on Capital Employed [ROCE] came in at -30.71%, up 13.91 percentage points from FY2024.

  • Annual Return on Capital Employed [ROCE] shows a five-year change of +5.49 percentage points (FY2020 to FY2025).
  • In prior years, 4D Molecular Therapeutics' Return on Capital Employed [ROCE] was -44.62% in FY2024 (-4.58 pp), -40.04% in FY2023 (-2.34 pp), -37.69% in FY2022 (-14.27 pp) and -23.42% in FY2021 (+12.78 pp).
  • Quarterly Return on Capital Employed [ROCE] has run from a low of -55.96% in Q3 2025 to a high of -21.67% in Q2 2024 over five years.
  • On a year-over-year basis, Return on Capital Employed [ROCE] increased in four of the last eight quarters, with an average year-over-year change of -7.29 percentage points.
  • The strongest year-over-year quarter for Return on Capital Employed [ROCE] in the past five years was Q1 2024, with a gain of 21.26 percentage points; the weakest was Q3 2025, with a drop of 27.06 percentage points.
  • According to Business Quant data, Return on Capital Employed [ROCE] for the three prior quarters was -36.17% (Q1 2026), -35.35% (Q4 2025) and -55.96% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 4D Molecular Therapeutics 875.59 Mn -584.35 Mn - -43.31%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -43.31%
Mar 31, 2026 -36.17%
Dec 31, 2025 -35.35%
Sep 30, 2025 -55.96%
Jun 30, 2025 -47.90%
Mar 31, 2025 -39.78%
Dec 31, 2024 -33.96%
Sep 30, 2024 -28.90%
Jun 30, 2024 -21.67%
Mar 31, 2024 -25.81%
Dec 31, 2023 -34.02%
Sep 30, 2023 -30.96%
Jun 30, 2023 -41.28%
Mar 31, 2023 -47.07%
Dec 31, 2022 -43.10%
Sep 30, 2022 -38.16%
Jun 30, 2022 -34.13%
Mar 31, 2022 -24.89%
Dec 31, 2021 -25.41%
Sep 30, 2021 -28.34%
API Access

4D Molecular Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=FDMT&period=max&api_key=YOUR_API_KEY